Acute Kidney Injury, Liver Diseases
Conditions
Keywords
dexmedetomidine, acute kidney injury, liver transplantation
Brief summary
Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.
Detailed description
Acute kidney injury (AKI) following liver transplantation (LT) has shown a wide range of incidence between 17% and 95% and is associated with increased costs, morbidity, and mortality. The etiology of AKI after LT is multifactorial. Among these factors, renal ischemia-reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as one of the most important independent risk factors and recent reports have indicated that IRI is associated with an inflammatory cascade. Dexmedetomidine which is a highly selective agonist of α2-adrenergic receptors has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.
Interventions
DRUGDexmedetomidine
The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
DRUGNormal saline
The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
Sponsors
Asan Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* living liver transplantation recipients
Exclusion criteria
* preoperative renal dysfunction * dual living donor liver transplantation * severe cerebral artery disease * severe cardio-pulmonary disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| acute kidney injury | 7 days | serum creatinine levels in postoperative 7 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| lactate level | 3 days | serial lactate level during operation and postoperative 3 days |
| delirium | postoperative day 7 | The incidence of delirium |
| early allograft dysfunction | postoperative day 7 | early allograft dysfunction |
| graft failure | 1 year | recipient death or re-transplantation within 1 year |
| intensive care unit length of stay | up to 1 year | intensive care unit length of stay (days) |
| hospital length of stay | up to 1 year | hospital length of stay (days) |
| duration of mechanical ventilation | up to 1 year | duration of mechanical ventilation (hours) |
Countries
South Korea
Outcome results
None listed